tiprankstipranks
Trending News
More News >
Integer Holdings Corporation (ITGR)
NYSE:ITGR

Integer Holdings (ITGR) AI Stock Analysis

Compare
152 Followers

Top Page

ITGR

Integer Holdings

(NYSE:ITGR)

Select Model
Select Model
Select Model
Neutral 65 (OpenAI - 5.2)
Rating:65Neutral
Price Target:
$92.00
▲(7.24% Upside)
Integer Holdings' overall score is driven by strong financial performance and positive corporate events. However, technical indicators suggest bearish momentum, and valuation metrics indicate limited upside potential. Earnings call insights reveal near-term challenges, impacting the overall outlook.
Positive Factors
Free Cash Flow Strength
Sustained FCF growth (12.38% TTM) and an operating cash flow to net income ratio near 1 indicate reliable cash conversion. That durability supports capex, R&D, potential M&A, and shareholder returns without depending on volatile capital markets, improving long-term financial flexibility.
Multi‑Year Revenue & Profit Expansion
Material multi-year growth (sales +39%, adj operating income +77%) signals scalable operations and effective commercialization. Persistent expansion across revenue and operating profit points to durable market penetration, supply chain scale benefits, and improved ability to invest in next‑gen products.
Share Repurchase Program
A $200M buyback program reflects board confidence and uses excess cash flow to enhance shareholder returns. Over the medium term this disciplined capital allocation can improve per‑share metrics, signal management conviction, and flexibly return capital while preserving operational investment capacity.
Negative Factors
Compressed Net Margins
A TTM net margin of 4.75% and declines in EBIT/EBITDA margins point to structural margin pressure from cost or pricing dynamics. Persistently thin margins reduce reinvestment capacity, lower return on equity, and make results more sensitive to cost inflation or mix shifts over the next several quarters.
Elevated Leverage
An expected leverage target near 2.7–2.8x, even if toward the lower end, implies meaningful debt sensitivity. Elevated leverage constrains strategic flexibility, raises interest expense risk in an uncertain rate environment, and limits the firm's ability to pursue large M&A or aggressive capex without de‑leveraging.
New Product Adoption Headwinds
Guidance cites declines for three new products and notable customer forecast changes, creating a 3–4% sales headwind plus a ~2% hit from a market exit. These structural adoption and demand risks can delay returns on R&D and disrupt medium‑term revenue rebuilding plans.

Integer Holdings (ITGR) vs. SPDR S&P 500 ETF (SPY)

Integer Holdings Business Overview & Revenue Model

Company DescriptionInteger Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through Medical and Non-Medical segments. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, urology, and gastroenterology procedures. It also provides cardiac rhythm management products, including implantable pacemakers, implantable cardioverter defibrillators, insertable cardiac monitors, implantable cardiac pacing and defibrillation leads, and heart failure therapies; neuromodulation products, such as implantable spinal cord stimulators; and non-rechargeable batteries, feedthroughs, device enclosures, machined components, and lead components and sub-assemblies. In addition, the company offers rechargeable batteries and chargers; and arthroscopic, laparoscopic, and general surgery devices and components, such as harmonic scalpels, shaver blades, burr shavers, radio frequency probes, biopsy probes, trocars, electrocautery components, wound dressings, GERD treatment components, and phacoemulsification needles. Further, it provides orthopedic products that include instruments used in hip, knee, and spine surgeries, as well as reamers and chisels. Additionally, the company offers customized battery power and power management systems, and battery solutions for the energy, military, and environmental markets. Furthermore, the company provides medical technologies. It serves multi-national original equipment manufacturers and their affiliated subsidiaries in the cardiac, neuromodulation, orthopedics, vascular, and advanced surgical and portable medical markets. Integer Holdings Corporation was founded in 1970 and is headquartered in Plano, Texas.
How the Company Makes MoneyInteger Holdings generates revenue through several key streams, primarily from the sale of medical devices and related services. The company's revenue model is centered around its core product offerings, which include implantable devices for cardiac rhythm management, neuromodulation, and orthopedic applications. Integer also earns income from contract manufacturing services, where it partners with other medical device companies to produce specialized products. Significant partnerships with major healthcare providers and OEMs (original equipment manufacturers) contribute to its earnings by securing long-term contracts and fostering innovation. Additionally, Integer's focus on research and development allows it to introduce new technologies and products, further enhancing its market presence and revenue potential.

Integer Holdings Earnings Call Summary

Earnings Call Date:Oct 24, 2025
(Q3-2025)
|
% Change Since: |
Next Earnings Date:Feb 19, 2026
Earnings Call Sentiment Neutral
Integer Holdings Corporation delivered strong results in the third quarter of 2025 and has shown significant growth over the past three years. However, a reduction in the financial outlook for 2025 and anticipated challenges in new product adoption for 2026 present concerns. While the company maintains a strong cash flow and plans for recovery by 2027, the immediate outlook is impacted by customer forecast changes and market exit strategies.
Q3-2025 Updates
Positive Updates
Strong Third Quarter Results
Sales grew 8% on a reported basis and 7% organically. Adjusted operating income increased 14%, and adjusted EPS grew 25% year-over-year to $1.79.
Record Growth Over Three Years
Sales increased by 39% from 2022 to 2025, adjusted operating income up 77%, and adjusted EPS up 73% at the midpoint of the outlook.
Positive Full Year 2025 Projections
Expected sales growth between 7% and 8%, adjusted operating income growth between 12% and 14%, and adjusted EPS growth between 19% and 21%.
Strong Cash Flow and Debt Management
Cash flow from operations expected to be between $230 million to $240 million, with free cash flow between $130 million and $140 million. Expected leverage ratio between 2.7 and 2.8x, towards the lower end of the target range.
Negative Updates
Reduction in 2025 Financial Outlook
Sales outlook reduced by $16 million due to recent changes in customer demand within the CRM&N product line. Adjusted operating income range reduced by $3 million, and adjusted EPS range reduced by $0.02.
Challenges with New Product Adoption
Sales of three new products expected to decline in 2026, leading to a 3% to 4% headwind in total company sales. Organic sales expected to be flat to up 4% in 2026.
Impact of Portable Medical Exit
The planned exit of the Portable Medical market is expected to be a headwind of approximately 2% to total sales in 2026.
Customer Forecast Changes
Unusual magnitude of changes in customer forecasts impacting multiple products, specifically two electrophysiology products and one neuromodulation product.
Company Guidance
During the Integer Holdings Corporation Third Quarter 2025 Earnings Call, the company provided updated guidance reflecting recent changes in customer forecasts and their impact on financial outlooks. For 2025, Integer revised its sales outlook downward by $16 million, expecting a 7% to 8% increase, with adjusted operating income projected to grow by 12% to 14%, and adjusted EPS by 19% to 21%. Despite strong Q3 results showing an 8% sales increase and a 25% rise in adjusted EPS, the company anticipates a challenging next three quarters due to reduced demand forecasts for specific new products in the CRM&N product line. For 2026, Integer expects sales to be flat to up 4% organically, with a reported sales range of down 2% to up 2%, impacted by a planned exit from the Portable Medical market. The company remains optimistic about returning to above-market organic sales growth in 2027, driven by a robust product development pipeline and strategic positioning in high-growth markets.

Integer Holdings Financial Statement Overview

Summary
Integer Holdings shows consistent revenue growth and strong cash flow generation. However, profitability margins are under pressure, and leverage has increased, indicating a need for improved cost management and debt reduction.
Income Statement
75
Positive
Integer Holdings has demonstrated consistent revenue growth, with a TTM increase of 2.02% and a solid gross profit margin of 26.89%. However, the net profit margin has decreased to 4.75% in the TTM, indicating some pressure on profitability. The EBIT and EBITDA margins have also shown a decline, suggesting increased operational costs or other financial pressures.
Balance Sheet
70
Positive
The company's debt-to-equity ratio of 0.75 in the TTM indicates a moderate level of leverage, which is manageable but has increased compared to previous years. The return on equity has decreased to 5.21%, reflecting a decline in profitability relative to shareholder equity. The equity ratio remains stable, suggesting a balanced approach to financing.
Cash Flow
80
Positive
Integer Holdings has shown strong free cash flow growth of 12.38% in the TTM, indicating improved cash generation capabilities. The operating cash flow to net income ratio is nearly 1, suggesting efficient cash conversion. The free cash flow to net income ratio of 0.91 further highlights robust cash flow management.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue1.83B1.72B1.56B1.33B1.22B1.07B
Gross Profit494.27M461.18M411.52M346.65M336.97M285.71M
EBITDA356.30M332.94M275.71M221.75M224.65M182.99M
Net Income86.90M119.90M90.65M66.38M96.81M77.26M
Balance Sheet
Total Assets3.40B3.08B2.94B2.79B2.58B2.37B
Cash, Cash Equivalents and Short-Term Investments58.94M46.54M23.67M24.27M17.89M49.21M
Total Debt1.31B1.10B1.05B1.01B905.81M777.55M
Total Liabilities1.65B1.46B1.42B1.38B1.23B1.10B
Stockholders Equity1.75B1.62B1.52B1.42B1.35B1.27B
Cash Flow
Free Cash Flow165.54M99.60M60.27M41.65M103.20M129.90M
Operating Cash Flow203.96M205.21M180.21M116.38M156.67M181.34M
Investing Cash Flow-205.65M-195.41M-163.37M-200.42M-271.00M-56.58M
Financing Cash Flow22.97M13.32M-18.01M92.48M81.99M-88.58M

Integer Holdings Technical Analysis

Technical Analysis Sentiment
Positive
Last Price85.79
Price Trends
50DMA
76.88
Positive
100DMA
84.67
Positive
200DMA
100.28
Negative
Market Momentum
MACD
2.51
Positive
RSI
65.51
Neutral
STOCH
64.84
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ITGR, the sentiment is Positive. The current price of 85.79 is above the 20-day moving average (MA) of 83.30, above the 50-day MA of 76.88, and below the 200-day MA of 100.28, indicating a neutral trend. The MACD of 2.51 indicates Positive momentum. The RSI at 65.51 is Neutral, neither overbought nor oversold. The STOCH value of 64.84 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ITGR.

Integer Holdings Risk Analysis

Integer Holdings disclosed 36 risk factors in its most recent earnings report. Integer Holdings reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Integer Holdings Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
76
Outperform
$4.73B56.9532.48%41.20%173.53%
69
Neutral
$2.38B56.256.54%16.81%34.90%
65
Neutral
$3.01B35.965.18%7.81%-26.32%
63
Neutral
$3.50B-15.94-17.63%8.97%-1024.86%
58
Neutral
$6.82B-79.91-12.19%30.38%47.64%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
47
Neutral
$2.27B-14.57-540.40%27.11%17.66%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
ITGR
Integer Holdings
85.90
-57.32
-40.02%
ATEC
Alphatec Holdings
15.26
3.20
26.53%
GKOS
Glaukos
123.94
-35.07
-22.06%
LIVN
LivaNova
63.91
13.18
25.98%
INSP
Inspire Medical Systems
82.01
-107.98
-56.83%
TMDX
TransMedics Group
140.99
75.46
115.15%

Integer Holdings Corporate Events

Business Operations and StrategyStock Buyback
Integer Holdings Announces $200M Share Repurchase Program
Positive
Nov 4, 2025

On November 3, 2025, Integer Holdings Corporation’s Board of Directors approved a share repurchase program allowing the company to buy back up to $200 million of its common stock. This initiative, announced on November 4, 2025, reflects the Board’s confidence in the company’s strategy and financial health, intending to use cash on hand and free cash flows for the repurchases. The program’s flexible nature allows management to execute repurchases opportunistically, potentially impacting the company’s stock value and shareholder returns positively.

The most recent analyst rating on (ITGR) stock is a Hold with a $69.00 price target. To see the full list of analyst forecasts on Integer Holdings stock, see the ITGR Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Dec 09, 2025